INCB18424 administration prevents aGvHD while preserving a robust GvT activity. A) Effect of INCB18424 on survival. Irradiated BALB/c mice received BM+SC cells from donors C57BL/6 (B6) and were treated or not with INCB18424 for 14 days at the three different doses of (INC90, INC45,INC22.5). Mice receiving B6 BM cells only (allogeneic) and syngeneic transplants were included. Data represent the pool of 2 independent experiments. N=15 each group, N=10 in control groups. B) GvHD score. Tissue sections of skin, liver, and intestine were graded by a veterinary pathologist on day 14 after allo-HSCT. C) Effect of INCB18424 on the survival of allo-HSCT recipients challenged with tumor cells. Allo-HSCT recipients were co-injected A20 (BM+SC+A20) or a RMBI (BM+SC+RMB-1) cells and treated or not with INCB18424 45mg/kg/day (BM+SC+A20+INC45; BM+SC+RMB1+INC45). Control mice did not receive SC (BM-A20; BM-RMB1). Data represent the pool of 2 independent experiments. N=10 each group.